Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing AnaptysBio鈥檚 dense immunology disclosures can feel like decoding a scientific journal. When the annual report 10-K stretches past 300 pages and each 8-K material event carries pipeline-moving details, locating what matters about somatic hyper-mutation spending or milestone revenue is time-consuming.
Stock Titan solves that problem. Our AI-powered summaries turn every AnaptysBio quarterly earnings report 10-Q filing and AnaptysBio insider trading Form 4 transactions into plain-English highlights鈥攏o more search-and-scroll. Receive real-time alerts the moment AnaptysBio Form 4 insider transactions real-time hit EDGAR, and let our platform surface context-rich charts that explain R&D burn, cash runway, and collaboration economics. Curious about executive pay? The AI links directly to the AnaptysBio proxy statement executive compensation sections you need.
Here鈥檚 what investors gain:
- 10-K simplified 鈥� critical risk factors, antibody pipeline updates, and patent positions extracted for quick review (AnaptysBio annual report 10-K simplified).
- 10-Q analysis 鈥� quarter-over-quarter shifts in R&D expense and partnership revenue with instant AnaptysBio earnings report filing analysis.
- Form 4 drill-downs 鈥� see every AnaptysBio executive stock transactions Form 4 alongside historical price charts.
- 8-K alerts 鈥� material trial results or collaboration amendments appear under 鈥�AnaptysBio 8-K material events explained鈥�.
Whether you鈥檙e understanding AnaptysBio SEC documents with AI for the first time or monitoring repeat insiders, Stock Titan delivers the transparency you need鈥攆aster than toggling through EDGAR links.
AnaptysBio, Inc. (ANAB) Form 144 shows an intended sale of 10,231 common shares with an aggregate market value of $200,712.78 to be executed on or about 08/08/2025 through Morgan Stanley Smith Barney on NASDAQ. The filing states these shares were acquired by a stock option exercise on 08/08/2025 with payment in cash. The notice also discloses prior sales by the same person, HOLLINGS C RENTON: 20,925 shares sold 07/02/2025 for $493,189.70 and 3,015 shares sold 06/18/2025 for $72,269.55. The signer represents there is no undisclosed material adverse information.
AnaptysBio is registering 1,650,000 additional shares of its common stock to be available under the Amended and Restated 2017 Equity Incentive Plan following stockholder approval. The filing makes those shares available for future awards to employees and directors and incorporates prior S-8 registrations and related company filings on file with the SEC.
Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC filed a Schedule 13G on 08/05/2025 disclosing a combined passive stake of 1,845,002 ANAB shares (6.3 % of outstanding) as of 06/30/2025. The parent company reports shared voting power over 1,841,919 shares and shared dispositive power over 1,845,002 shares; it holds no sole voting or dispositive authority.
The subsidiary individually owns 1,525,502 shares (5.2 %) with fully shared voting and dispositive power. The filing is made under Rule 13d-1(b), classifying Morgan Stanley as a parent holding company/control person (HC, CO) and the subsidiary as a broker-dealer (BD, CO). Both certify the shares were acquired in the ordinary course of business and not for the purpose of influencing control of AnaptysBio.
Director Dennis M. Fenton of AnaptysBio reported a significant insider transaction on June 18, 2025. The filing details:
- Sale of 3,015 shares of Common Stock at $23.97 per share
- Transaction was executed under a Rule 10b5-1 trading plan established on March 22, 2024
- The sale was primarily to satisfy tax obligations related to restricted stock unit vesting on June 15, 2025
- Following the transaction, Fenton retains direct ownership of 4,965 shares
This transaction appears to be a planned sale for tax purposes rather than a discretionary trade, as evidenced by the pre-established 10b5-1 plan. The sale represents a partial liquidation of Fenton's holdings, maintaining a significant ownership position in the company.
FAQ
What is the current stock price of Anaptysbio (ANAB)?
What is the market cap of Anaptysbio (ANAB)?
